JP2018505146A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505146A5
JP2018505146A5 JP2017533789A JP2017533789A JP2018505146A5 JP 2018505146 A5 JP2018505146 A5 JP 2018505146A5 JP 2017533789 A JP2017533789 A JP 2017533789A JP 2017533789 A JP2017533789 A JP 2017533789A JP 2018505146 A5 JP2018505146 A5 JP 2018505146A5
Authority
JP
Japan
Prior art keywords
amino
ethoxy
chem
acetyl
carboxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017533789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018505146A (ja
JP6727210B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/080969 external-priority patent/WO2016102562A1/en
Publication of JP2018505146A publication Critical patent/JP2018505146A/ja
Publication of JP2018505146A5 publication Critical patent/JP2018505146A5/ja
Application granted granted Critical
Publication of JP6727210B2 publication Critical patent/JP6727210B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017533789A 2014-12-23 2015-12-22 Fgf21誘導体及びその使用 Active JP6727210B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199935 2014-12-23
EP14199935.9 2014-12-23
PCT/EP2015/080969 WO2016102562A1 (en) 2014-12-23 2015-12-22 Fgf21 derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2018505146A JP2018505146A (ja) 2018-02-22
JP2018505146A5 true JP2018505146A5 (enExample) 2018-11-29
JP6727210B2 JP6727210B2 (ja) 2020-07-22

Family

ID=52130150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533789A Active JP6727210B2 (ja) 2014-12-23 2015-12-22 Fgf21誘導体及びその使用

Country Status (24)

Country Link
US (3) US9744213B2 (enExample)
EP (1) EP3236991B1 (enExample)
JP (1) JP6727210B2 (enExample)
KR (1) KR102427527B1 (enExample)
CN (1) CN107108709B (enExample)
AR (1) AR103246A1 (enExample)
AU (1) AU2015371056B2 (enExample)
DK (1) DK3236991T3 (enExample)
ES (1) ES2742503T3 (enExample)
HK (1) HK1246156B (enExample)
HR (1) HRP20191292T1 (enExample)
HU (1) HUE044783T2 (enExample)
IL (1) IL252438B (enExample)
MX (1) MX377044B (enExample)
MY (1) MY181181A (enExample)
PL (1) PL3236991T3 (enExample)
PT (1) PT3236991T (enExample)
RS (1) RS59154B1 (enExample)
RU (1) RU2729011C2 (enExample)
SA (1) SA517381673B1 (enExample)
SI (1) SI3236991T1 (enExample)
TW (2) TWI708781B (enExample)
WO (1) WO2016102562A1 (enExample)
ZA (1) ZA201703768B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45113A (fr) 2016-05-24 2019-04-10 Novo Nordisk As Composés mic-1 et leur utilisation
CN106421753A (zh) * 2016-10-19 2017-02-22 哈尔滨医科大学 重组人成纤维细胞生长因子‑21在制备预防和治疗缺血性心律失常药物中的应用
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1化合物及其用途
KR102229037B1 (ko) * 2017-09-04 2021-03-17 89바이오 리미티드 돌연변이 fgf-21 펩티드 접합체 및 이의 용도
AU2019297327A1 (en) 2018-07-03 2021-02-18 Bristol-Myers Squibb Company FGF21 formulations
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
WO2022238503A1 (en) 2021-05-11 2022-11-17 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도
KR20240034235A (ko) 2021-07-14 2024-03-13 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 대사 장애를 위한 융합 폴리펩타이드
CN116162145A (zh) * 2021-09-08 2023-05-26 北京志道生物科技有限公司 一种fgf21突变蛋白及其应用
US12098400B2 (en) * 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
PE20251082A1 (es) 2022-07-08 2025-04-10 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
PE20252745A1 (es) 2023-03-30 2025-12-05 Novo Nordisk As Compuestos de fusion y usos de estos
CN121194798A (zh) * 2023-05-12 2025-12-23 诺和诺德股份有限公司 长效生长激素受体拮抗剂及其用途
AR133774A1 (es) 2023-09-11 2025-10-29 Novo Nordisk As Anticuerpos de dominio anti-il-6
CN118307684B (zh) * 2024-06-11 2024-10-18 北京志道生物科技有限公司 一种经脂肪酸链修饰的glp-1-fgf21融合蛋白及其制备方法和应用
WO2026012311A1 (zh) * 2024-07-08 2026-01-15 浙江道尔生物科技有限公司 Fgf21衍生物及其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Glp―1誘導体
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Glp−1アナログ複合タンパク質
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 glp-1 유도체
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
AU2004303783A1 (en) 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
CA2550050A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
WO2005091944A2 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
PL1751184T3 (pl) 2004-05-13 2010-02-26 Lilly Co Eli Białka fuzyjne FGF-21
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
ES2564167T3 (es) 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
DK1789442T3 (da) 2004-09-02 2009-11-16 Lilly Co Eli Muteiner af fibroblastvækstfaktor 21
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
EP1831371A2 (en) 2004-12-14 2007-09-12 Eli Lilly And Company Muteins of fibroblast growth factor 21
WO2006078463A2 (en) 2005-01-21 2006-07-27 Eli Lilly And Company Method for treating cardiovascular disease
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 fgf-21 폴리펩티드 및 그 용도
SI2068909T1 (sl) 2007-03-30 2012-09-28 Ambrx Inc Modificirani fgf-21 polipeptidi in njihova uporaba
US20110034373A1 (en) 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN100587073C (zh) 2008-03-24 2010-02-03 吉林农大生物反应器工程有限公司 人成纤维细胞生长因子-21的重组表达
MX2010013333A (es) * 2008-06-04 2011-04-05 Amgen Inc Mutantes fgf21 y usos de los mismos.
EA032727B1 (ru) * 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
KR20110117666A (ko) * 2009-01-23 2011-10-27 노보 노르디스크 에이/에스 알부민 바인더 a-b-c-d-e-를 갖는 fgf21 유도체 및 그것의 사용
US20120052069A1 (en) * 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
TWI560197B (en) 2009-05-05 2016-12-01 Amgen Inc Fgf21 mutants and uses thereof
US20120035099A1 (en) 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
WO2011154349A2 (en) * 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
US20120172298A1 (en) 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
EP2595647A1 (en) * 2010-07-20 2013-05-29 Novo Nordisk A/S N-terminal modified fgf21 compounds
EP2750695A2 (en) * 2011-08-31 2014-07-09 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
CA2880929A1 (en) * 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
IL292303A (en) * 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease

Similar Documents

Publication Publication Date Title
RU2017125050A (ru) Производные fgf21 и их применения
JP2013532644A5 (enExample)
JP2013533227A5 (enExample)
JP2012529463A5 (enExample)
MY161450A (en) Double-acylated glp-1 derivatives
HRP20201881T1 (hr) Spojevi koji su suagonisti glukagona i glp-1
JP2013543497A5 (enExample)
JP2017528419A5 (enExample)
PH12019500074A1 (en) Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
FI3727426T3 (fi) Inkretiinianalogeja ja niiden käyttötarkoituksia
JP2017500289A5 (enExample)
JP2017502024A5 (enExample)
JP2016500682A5 (enExample)
JP2012506402A5 (enExample)
CY1113299T1 (el) Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο
JP2016526012A5 (enExample)
JP2014224121A5 (enExample)
JP2016153410A5 (enExample)
JP2017081939A5 (enExample)
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
ATE527353T1 (de) Pdgf-bindendes polypeptid aus protein a
JP2013518115A5 (enExample)
WO2012069836A3 (en) Biologically active complex and its preparation
EP3963063A4 (en) COMPOSITIONS FOR THE TREATMENT OF PUMP DISEASE
JP2016523241A5 (enExample)